Mye-EUNITER
 

Movahedi, Kiavash

Our mission is to use the heterogeneity of myeloid cells (MCs) as an in vivo sensor to track inflammatory responses and as a target for therapeutic intervention. MC heterogeneity is studied from the perspective of ontogeny and activation state in selected inflamed tissues, in particular in the liver (Kupffer cells) and tumors (hypoxic and normoxic tumor-associated macrophages, myeloid-derived suppressor cell subpopulations).

Based on markers that allow discriminating between selected MC subpopulations, we fully invest in the development of tools to visualize and modulate the in vivo differentiation, recruitment and function of selected MC subpopulations in inflamed tissues. These include in particular the identification of Kupffer cell-specific markers and markers for different tumor-associated macrophage or dendritic cell populations to generate transgenic (knock-in) mice allowing tracking and ablating selected MC populations to evaluate their role in homeostasis and in distinct models of liver injury and tumor growth, respectively. We also fully exploit the strategic advantage of Nanobodies® as tools for in vivo imaging and therapeutic targeting of MCs.

Models available:

  • Immunobiology of myeloid cells, mainly monocytes, macrophages and dendritic cells, in cancer and parasitic diseases

Cells available:

  • Macrophages (mainly in tumors, liver and brain)
  • Myeloid-derived-suppressor cells

Technology available:

  • Multiple in vitro and in vivo immunological techniques
  • Flow cytometry
  • Nanobody technology
  • Surface Plasmon Resonance
  • Access to several core facilities such as the Imaging Core Facility (state of the art microscopy), the Genomics Core Facility (microarrays, RNAseq,...)

Key publications related to Mye-EUNITER:

  1. Movahedi K, Van Ginderachter JA. (2016). The ontogeny and microenvironmental regulation of Tumor-Associated Macrophages. Antioxid Redox Signal (in Press)  
  2. Movahedi K, Schoonooghe S, Laoui D, Houbracken I, Waelput W, Breckpot K, Bouwens L, Lahoutte T, De Baetselier P, Raes G, Devoogdt N, Van Ginderachter J.A. Nanobody-based targeting of the Macrophage Mannose Receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res, 2012, Vol 72(16): 4165-4177 
  3. Movahedi K., Laoui D., Gysemans C., Baeten M., Stangé G., Van den Bossche J., Mack M., Pipeleers D., In’t Veld P., De Baetselier P., and Van Ginderachter J.A. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res, 2010, Vol 70: 5728-5739 
  4. Guilliams M, Movahedi K, Bosschaerts T, VandenDriessche T, Chuah MK, Herin M, Acosta-Sanchez A, Ma L, Moser M, Van Ginderachter JA, Brys L, De Baetselier P, Beschin A. (2009). IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. Journal of Immunology. 182:1107-18. 
  5. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., De Baetselier P., and Van Ginderachter J.A. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. Blood, 2008, Vol 111: 4233-4244.